X

Trial Profile

A Study to Evaluate Safety and Efficacy of IBI306 in Patients With Heterozygous Familial Hypercholesterolemia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tafolecimab (Primary)
Indications Hyperlipoproteinaemia type IIa
Focus Registrational; Therapeutic Use
Sponsors Innovent Biologics

Most Recent Events

13 Sep 2022 Status changed from active, no longer recruiting to completed.
04 Apr 2022 Results assessing efficacy and safety of tafolecimab, presented at the 71st Annual Scientific Session of the American College of Cardiology.
03 Apr 2022 According to an Innovent Biologics media release, Primary endpoint (Percentage of LDL-C decreased from baseline injection 450 mg Q4W) has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com